{"entity":{"id":"igor-puzanov","kind":"person","name":"Igor Puzanov","aka":[],"tldr":"Led the first talimogene laherparepvec plus ipilimumab study and co-wrote the immune toxicity management guidelines.","summary":"Igor Puzanov is Director of the Early Phase Clinical Trials Program and Chief of the Melanoma Section at Roswell Park Comprehensive Cancer Center. He is a melanoma oncologist known for leading the first study of the oncolytic virus talimogene laherparepvec combined with ipilimumab, and for co-writing the guidelines on managing immune-related toxicity. His selected paper reports talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB to IV melanoma. He now directs Roswell Park's phase 1 programme and continues to work on oncolytic viruses.","asOf":"2026-09-08","links":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/igor-puzanov"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["oncolytic-virus"],"targets":[],"drugs":["talimogene-laherparepvec","ipilimumab"],"companies":[],"institutions":["roswell-park"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Director, Early Phase Clinical Trials Program; Chief, Melanoma Section","institutionId":"roswell-park","specialisms":["Melanoma","Oncolytic viruses","Immune-related toxicity"],"profiles":[{"label":"Roswell Park profile","url":"https://www.roswellpark.org/igor-puzanov"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Puzanov%20I%5BAuthor%5D"}],"papers":[{"title":"Talimogene laherparepvec in combination with ipilimumab in previously untreated, unresectable stage IIIB-IV melanoma","journal":"Journal of Clinical Oncology","year":2016,"url":"https://doi.org/10.1200/JCO.2016.67.1529","doi":"10.1200/JCO.2016.67.1529"}],"orcid":"0000-0002-9803-3497"},"route":"/people/igor-puzanov/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"}],"drug":[{"id":"ipilimumab","kind":"drug","name":"Ipilimumab","route":"/drugs/ipilimumab/"},{"id":"talimogene-laherparepvec","kind":"drug","name":"Talimogene laherparepvec","route":"/drugs/talimogene-laherparepvec/"}],"institution":[{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","route":"/institutions/roswell-park/"}]}}